User menu

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.

Bibliographic reference Defour, Jean-Philippe ; Chachoua, Ilyas ; Pecquet, Christian ; Constantinescu, Stefan N.. Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.. In: Leukemia, Vol. 30, no. 5, p. 1214-1216 (2015)
Permanent URL
  1. Skoda Radek C., Duek Adrian, Grisouard Jean, Pathogenesis of myeloproliferative neoplasms, 10.1016/j.exphem.2015.06.007
  2. Sangkhae V., Etheridge S. L., Kaushansky K., Hitchcock I. S., The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm, 10.1182/blood-2014-07-587238
  3. Staerk J., An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor, 10.1182/blood-2005-06-2600
  4. Defour J.-P., Itaya M., Gryshkova V., Brett I. C., Pecquet C., Sato T., Smith S. O., Constantinescu S. N., Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation, 10.1073/pnas.1211560110
  5. Abe M, Suzuki K, Inagaki O, Sassa S, Shikama H, A novel MPL point mutation resulting in thrombopoietin-independent activation, 10.1038/sj.leu.2402554
  6. Pikman Yana, Lee Benjamin H, Mercher Thomas, McDowell Elizabeth, Ebert Benjamin L, Gozo Maricel, Cuker Adam, Wernig Gerlinde, Moore Sandra, Galinsky Ilene, DeAngelo Daniel J, Clark Jennifer J, Lee Stephanie J, Golub Todd R, Wadleigh Martha, Gilliland D. Gary, Levine Ross L, MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, 10.1371/journal.pmed.0030270
  7. Pardanani A. D., Levine R. L., Lasho T., Pikman Y., Mesa R. A., Wadleigh M., Steensma D. P., Elliott M. A., Wolanskyj A. P., Hogan W. J., McClure R. F., Litzow M. R., Gilliland D. G., Tefferi A., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, 10.1182/blood-2006-04-018879
  8. Pecquet C., Staerk J., Chaligne R., Goss V., Lee K. A., Zhang X., Rush J., Van Hees J., Poirel H. A., Scheiff J.-M., Vainchenker W., Giraudier S., Polakiewicz R. D., Constantinescu S. N., Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor, 10.1182/blood-2008-10-183558
  9. Boyd Elaine M., Bench Anthony J., Goday-Fernández Andrea, Anand Shubha, Vaghela Krishna J., Beer Phillip, Scott Mike A., Bareford David, Green Anthony R., Huntly Brian, Erber Wendy N., Clinical utility of routineMPLexon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis, 10.1111/j.1365-2141.2010.08083.x
  10. Ma Wanlong, Zhang Xi, Wang Xiuqiang, Zhang Zhong, Yeh Chen-Hsiung, Uyeji Jennifer, Albitar Maher, MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders : , 10.1097/pdm.0b013e3181ecd261
  11. Beer P. A., Campbell P. J., Scott L. M., Bench A. J., Erber W. N., Bareford D., Wilkins B. S., Reilly J. T., Hasselbalch H. C., Bowman R., Wheatley K., Buck G., Harrison C. N., Green A. R., MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, 10.1182/blood-2008-01-131664
  12. Pardanani A, Guglielmelli P, Lasho T L, Pancrazzi A, Finke C M, Vannucchi A M, Tefferi A, Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients, 10.1038/leu.2011.161
  13. Ding J., Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin, 10.1182/blood-2003-10-3471
  14. Venancio Thiago M., Aravind L., CYSTM, a novel cysteine-rich transmembrane module with a role in stress tolerance across eukaryotes, 10.1093/bioinformatics/btp647
  15. Heitmann P., A Model for Sulfhydryl Groups in Proteins. Hydrophobic Interactions of the Cysteine Side Chain in Micelles, 10.1111/j.1432-1033.1968.tb19535.x